The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

  • 1.

    SiegelRNaishadhamDJemalA. Cancer statistics, 2013. CA Cancer J Clin2013;63:1130.

  • 2.

    ChengLEngCNiemanLZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol2011;34:573580.

    • Search Google Scholar
    • Export Citation
  • 3.

    SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 4.

    LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699704.

    • Search Google Scholar
    • Export Citation
  • 5.

    Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:22122221.

    • Search Google Scholar
    • Export Citation
  • 6.

    YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202207.

    • Search Google Scholar
    • Export Citation
  • 7.

    AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:92439249.

    • Search Google Scholar
    • Export Citation
  • 8.

    DawoodOMahadevanAGoodmanKA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer2009;45:29472959.

  • 9.

    KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:1161-1176 1179.

  • 10.

    MuratoreAZorziDBouzariH. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?Ann Surg Oncol2007;14:766770.

    • Search Google Scholar
    • Export Citation
  • 11.

    FongYCohenAMFortnerJG. Liver resection for colorectal metastases. J Clin Oncol1997;15:938946.

  • 12.

    HayashiMInoueYKomedaK. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg2010;10:27.

    • Search Google Scholar
    • Export Citation
  • 13.

    TsaiMSSuYHHoMC. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol2007;14:786794.

    • Search Google Scholar
    • Export Citation
  • 14.

    FosterJH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis1984;4:170179.

  • 15.

    StanglRAltendorf-HofmannACharnleyRMScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:14051410.

    • Search Google Scholar
    • Export Citation
  • 16.

    AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644657.

    • Search Google Scholar
    • Export Citation
  • 17.

    ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759766.

    • Search Google Scholar
    • Export Citation
  • 18.

    EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900909.

    • Search Google Scholar
    • Export Citation
  • 19.

    FongYSaloJ. Surgical therapy of hepatic colorectal metastasis. Semin Oncol1999;26:514523.

  • 20.

    PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715722.

    • Search Google Scholar
    • Export Citation
  • 21.

    AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737739.

    • Search Google Scholar
    • Export Citation
  • 22.

    BilchikAJPostonGCurleySA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;23:90739078.

  • 23.

    ChotiMA. Chemotherapy-associated hepatotoxicity: do we need to be concerned?Ann Surg Oncol2009;16:23912394.

  • 24.

    KishiYZorziDContrerasCM. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol2010;17:28702876.

    • Search Google Scholar
    • Export Citation
  • 25.

    Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15:460466.

    • Search Google Scholar
    • Export Citation
  • 26.

    VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:20652072.

    • Search Google Scholar
    • Export Citation
  • 27.

    PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933939.

    • Search Google Scholar
    • Export Citation
  • 28.

    DelaunoitTAlbertsSRSargentDJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425429.

    • Search Google Scholar
    • Export Citation
  • 29.

    FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:16701676.

    • Search Google Scholar
    • Export Citation
  • 30.

    SouglakosJAndroulakisNSyrigosK. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer2006;94:798805.

    • Search Google Scholar
    • Export Citation
  • 31.

    MasiGVasileELoupakisF. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst2011;103:2130.

    • Search Google Scholar
    • Export Citation
  • 32.

    FolprechtGGruenbergerTBechsteinWO. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol2010;11:3847.

    • Search Google Scholar
    • Export Citation
  • 33.

    TanBRZubalBHawkinsW. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Presented at the 2009 Gastrointestinal Cancers Symposium; January15-172009; San Francisco, California. Abstract 497.

    • Search Google Scholar
    • Export Citation
  • 34.

    YeLCLiuTSRenL. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol2013;31:19311938.

    • Search Google Scholar
    • Export Citation
  • 35.

    PetrelliFBarniS. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis2012;27:9971004.

    • Search Google Scholar
    • Export Citation
  • 36.

    FuchsCSMarshallJMitchellE. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol2007;25:47794786.

    • Search Google Scholar
    • Export Citation
  • 37.

    HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 38.

    SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:20132019.

    • Search Google Scholar
    • Export Citation
  • 39.

    AdamRAvisarEAricheA. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol2001;8:347353.

    • Search Google Scholar
    • Export Citation
  • 40.

    PawlikTMOlinoKGleisnerAL. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg2007;11:860868.

    • Search Google Scholar
    • Export Citation
  • 41.

    RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:22832292.

    • Search Google Scholar
    • Export Citation
  • 42.

    CilibertoDPratiURovedaL. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep2012;27:18491856.

    • Search Google Scholar
    • Export Citation
  • 43.

    AraujoRGonenMAllenP. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol2013;20:43124321.

    • Search Google Scholar
    • Export Citation
  • 44.

    BilchikAJPostonGAdamRChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol2008;26:53205321.

    • Search Google Scholar
    • Export Citation
  • 45.

    LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:20382048.

    • Search Google Scholar
    • Export Citation
  • 46.

    van VledderMGde JongMCPawlikTM. Disappearing colorectal liver metastases after chemotherapy: should we be concerned?J Gastrointest Surg2010;14:16911700.

    • Search Google Scholar
    • Export Citation
  • 47.

    BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:39393945.

    • Search Google Scholar
    • Export Citation
  • 48.

    AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 49.

    AndreTLouvetCMaindrault-GoebelF. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer1999;35:13431347.

    • Search Google Scholar
    • Export Citation
  • 50.

    BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:12841292.

    • Search Google Scholar
    • Export Citation
  • 51.

    BurokerTRO'ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:1420.

    • Search Google Scholar
    • Export Citation
  • 52.

    CassidyJClarkeSDiaz-RubioE. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol2008;26:20062012.

    • Search Google Scholar
    • Export Citation
  • 53.

    CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393399.

    • Search Google Scholar
    • Export Citation
  • 54.

    ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol2005;23:48664875.

    • Search Google Scholar
    • Export Citation
  • 55.

    CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 56.

    CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:14131418.

    • Search Google Scholar
    • Export Citation
  • 57.

    de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808815.

    • Search Google Scholar
    • Export Citation
  • 58.

    de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 59.

    DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer2004;101:21702176.

    • Search Google Scholar
    • Export Citation
  • 60.

    DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:10411047.

    • Search Google Scholar
    • Export Citation
  • 61.

    DouillardJYSienaSCassidyJ. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28:46974705.

    • Search Google Scholar
    • Export Citation
  • 62.

    FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807814.

    • Search Google Scholar
    • Export Citation
  • 63.

    GiantonioBJCatalanoPJMeropolNJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol2007;25:15391544.

    • Search Google Scholar
    • Export Citation
  • 64.

    GoldbergRM. Therapy for metastatic colorectal cancer. Oncologist2006;11:981987.

  • 65.

    GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:3850.

    • Search Google Scholar
    • Export Citation
  • 66.

    GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 67.

    GrotheyAVan CutsemESobreroA. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013;381:303312.

    • Search Google Scholar
    • Export Citation
  • 68.

    HallerDGRothenbergMLWongAO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol2008;26:45444550.

    • Search Google Scholar
    • Export Citation
  • 69.

    HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:35023508.

    • Search Google Scholar
    • Export Citation
  • 70.

    JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 71.

    KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:37063712.

    • Search Google Scholar
    • Export Citation
  • 72.

    KellyHGoldbergRM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol2005;23:45534560.

    • Search Google Scholar
    • Export Citation
  • 73.

    KohneCMineurLGreilR. Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January22-242010; Orlando, Florida. Abstract 414.

    • Search Google Scholar
    • Export Citation
  • 74.

    Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:13381342.

    • Search Google Scholar
    • Export Citation
  • 75.

    PeetersMPriceTJCervantesA. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol2010;28:47064713.

    • Search Google Scholar
    • Export Citation
  • 76.

    PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:15591565.

    • Search Google Scholar
    • Export Citation
  • 77.

    PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) [abstract]. J Clin Oncol2008;26(Suppl):Abstract LBA4011.

    • Search Google Scholar
    • Export Citation
  • 78.

    ReidyDLChungKYTimoneyJP. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol2007;25:26912695.

  • 79.

    SaltzLClarkeSDiaz-RubioE. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. J Clin Oncol2007;25(Suppl):Abstract 4028.

    • Search Google Scholar
    • Export Citation
  • 80.

    Van CutsemE. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist2006;11:10101017.

  • 81.

    Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:11901197.

    • Search Google Scholar
    • Export Citation
  • 82.

    Van CutsemEKohneCHHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360:14081417.

    • Search Google Scholar
    • Export Citation
  • 83.

    Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:16581664.

    • Search Google Scholar
    • Export Citation
  • 84.

    Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:40974106.

    • Search Google Scholar
    • Export Citation
  • 85.

    Van CutsemETaberneroJLakomyR. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol2012;30:34993506.

    • Search Google Scholar
    • Export Citation
  • 86.

    WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:18791887.

    • Search Google Scholar
    • Export Citation
  • 87.

    LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:2133.

    • Search Google Scholar
    • Export Citation
  • 88.

    O'DwyerPJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist2006;11:992998.

  • 89.

    RaymondEFaivreSWoynarowskiJMChaneySG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol1998;25:412.

  • 90.

    RothenbergMLBlankeCD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol1999;26:632639.

  • 91.

    TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 92.

    CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:20842091.

    • Search Google Scholar
    • Export Citation
  • 93.

    PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:42174223.

    • Search Google Scholar
    • Export Citation
  • 94.

    DucreuxMMalkaDMendiboureJ. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol2011;12:10321044.

    • Search Google Scholar
    • Export Citation
  • 95.

    KoopmanMAntoniniNFDoumaJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet2007;370:135142.

    • Search Google Scholar
    • Export Citation
  • 96.

    SeymourMTMaughanTSLedermannJA. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet2007;370:143152.

    • Search Google Scholar
    • Export Citation
  • 97.

    SargentDJKohneCHSanoffHK. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol2009;27:19481955.

    • Search Google Scholar
    • Export Citation
  • 98.

    NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet2008;371:10071016.

    • Search Google Scholar
    • Export Citation
  • 99.

    NordlingerBSorbyeHGlimeliusB. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results [abstract]. J Clin Oncol2012;30(Suppl):Abstract 3508.

    • Search Google Scholar
    • Export Citation
  • 100.

    KidwellKMYothersGGanzPA. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer2012;118:56145622.

    • Search Google Scholar
    • Export Citation
  • 101.

    TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol2006;24:394400.

    • Search Google Scholar
    • Export Citation
  • 102.

    SeymourM. Conceptual approaches to metastatic disease. Ann Oncol2012;23(Suppl 10):x7780.

  • 103.

    GamelinLBoisdron-CelleMDelvaR. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res2004;10:40554061.

    • Search Google Scholar
    • Export Citation
  • 104.

    GamelinLBoisdron-CelleMMorelA. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol2008;26:11881189; author reply 1189-1190.

    • Search Google Scholar
    • Export Citation
  • 105.

    GrotheyANikcevichDASloanJA. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol2011;29:421427.

    • Search Google Scholar
    • Export Citation
  • 106.

    HochsterHSGrotheyAChildsBH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol2007;25:40284029.

    • Search Google Scholar
    • Export Citation
  • 107.

    KnijnNTolJKoopmanM. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer2010;47:369374.

    • Search Google Scholar
    • Export Citation
  • 108.

    KurnialiPCLuoLGWeitbergAB. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park)2010;24:289292.

    • Search Google Scholar
    • Export Citation
  • 109.

    WenFZhouYWangW. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol2013;24:171178.

    • Search Google Scholar
    • Export Citation
  • 110.

    WuZOuyangJHeZZhangS. Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer2012;48:17911798.

    • Search Google Scholar
    • Export Citation
  • 111.

    LoprinziCLQinRDakhilSR. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: an alliance for clinical trials in oncology study [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3501.

    • Search Google Scholar
    • Export Citation
  • 112.

    ChibaudelBMaindrault-GoebelFLledoG. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol2009;27:57275733.

    • Search Google Scholar
    • Export Citation
  • 113.

    HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol2008;26:35233529.

    • Search Google Scholar
    • Export Citation
  • 114.

    BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663671.

    • Search Google Scholar
    • Export Citation
  • 115.

    CassidyJClarkeSDiaz-RubioE. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer2011;105:5864.

    • Search Google Scholar
    • Export Citation
  • 116.

    DucreuxMBennounaJHebbarM. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer2011;128:682690.

    • Search Google Scholar
    • Export Citation
  • 117.

    ZhangCWangJGuH. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncol Lett2012;3:831838.

    • Search Google Scholar
    • Export Citation
  • 118.

    ELOXATIN [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2011.

  • 119.

    XELODA [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2011.

  • 120.

    HallerDGCassidyJClarkeSJ. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol2008;26:21182123.

    • Search Google Scholar
    • Export Citation
  • 121.

    SchmollHJArnoldD. Update on capecitabine in colorectal cancer. Oncologist2006;11:10031009.

  • 122.

    HofheinzRDHeinemannVvon WeikersthalLF. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer2012;107:16781683.

    • Search Google Scholar
    • Export Citation
  • 123.

    Camptosar [package insert]. New York, NY: Pfizer, Inc.; 2010.

  • 124.

    InnocentiFUndeviaSDIyerL. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol2004;22:13821388.

    • Search Google Scholar
    • Export Citation
  • 125.

    The impact of pharmacogenetic testing: UGT1A1 for irinotecan toxicity: managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar® CPT-11). LabCorp Laboratory Corporation of America Web site.

    • Search Google Scholar
    • Export Citation
  • 126.

    LiuXChengDKuangQ. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J2014;14:120129.

    • Search Google Scholar
    • Export Citation
  • 127.

    O'DwyerPJCatalanoRB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol2006;24:45344538.

    • Search Google Scholar
    • Export Citation
  • 128.

    The Invader UGT1A1 Molecular Assay HOLOGIC. Invader Chemistry Web site. Available at: http://www.invaderchemistry.com/invader_applications/invader-ugt1a1.html. Accessed January 27 2104.

    • Search Google Scholar
    • Export Citation
  • 129.

    SobreroAAcklandSClarkeS. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology2009;77:113119.

    • Search Google Scholar
    • Export Citation
  • 130.

    Van CutsemELangIFolprechtG. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]. J Clin Oncol2010;28(Suppl):Abstract 3570.

    • Search Google Scholar
    • Export Citation
  • 131.

    MitryEFieldsALABleibergH. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:49064911.

    • Search Google Scholar
    • Export Citation
  • 132.

    CunninghamDLangIMarcuelloE. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol2013;14:10771085.

    • Search Google Scholar
    • Export Citation
  • 133.

    FalconeACremoliniCMasiG. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3505.

    • Search Google Scholar
    • Export Citation
  • 134.

    LoupakisFCremoliniCMasiG. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial [abstract]. J Clin Oncol2013;31(Suppl):Abstract 336.

    • Search Google Scholar
    • Export Citation
  • 135.

    GruenbergerTBridgewaterJAChauI. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3619.

    • Search Google Scholar
    • Export Citation
  • 136.

    AVASTIN [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.

  • 137.

    KabbinavarFHurwitzHIFehrenbacherL. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol2003;21:6065.

    • Search Google Scholar
    • Export Citation
  • 138.

    KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:36973705.

    • Search Google Scholar
    • Export Citation
  • 139.

    SnoerenNVoestEEBergmanAM. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer2010;10:545.

    • Search Google Scholar
    • Export Citation
  • 140.

    CaoYTanAGaoF. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis2009;24:677685.

    • Search Google Scholar
    • Export Citation
  • 141.

    HurwitzHITebbuttNCKabbinavarF. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist2013;18:10041012.

    • Search Google Scholar
    • Export Citation
  • 142.

    LoupakisFBriaEVaccaroV. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res2010;29:58.

    • Search Google Scholar
    • Export Citation
  • 143.

    LvCWuSZhengD. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm2013;28:501509.

    • Search Google Scholar
    • Export Citation
  • 144.

    WelchSSpithoffKRumbleRBMarounJ. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol2010;21:11521162.

    • Search Google Scholar
    • Export Citation
  • 145.

    MacedoLTda Costa LimaABSasseAD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer2012;12:89.

    • Search Google Scholar
    • Export Citation
  • 146.

    MeyerhardtJALiLSanoffHK. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol2012;30:608615.

    • Search Google Scholar
    • Export Citation
  • 147.

    HartmannHMullerJMarschnerN. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?J Clin Oncol2012;30:33173318; author reply 3318.

    • Search Google Scholar
    • Export Citation
  • 148.

    HurwitzHILymanGH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?J Clin Oncol2012;30:580581.

    • Search Google Scholar
    • Export Citation
  • 149.

    AllegraCJYothersGO'ConnellMJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol2011;29:1116.

    • Search Google Scholar
    • Export Citation
  • 150.

    de GramontACutsemEVTaberneroJ. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J Clin Oncol2011;29(Suppl 4):Abstract 362.

    • Search Google Scholar
    • Export Citation
  • 151.

    RanpuraVHapaniSWuS. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA2011;305:487494.

  • 152.

    HurwitzHISaltzLBVan CutsemE. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol2011;29:17571764.

    • Search Google Scholar
    • Export Citation
  • 153.

    DaiFShuLBianY. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig2013;33:779788.

    • Search Google Scholar
    • Export Citation
  • 154.

    ScappaticciFAFehrenbacherLCartwrightT. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173180.

    • Search Google Scholar
    • Export Citation
  • 155.

    CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 156.

    Safety: Avastin (bevacizumab). U.S. Food and Drug Administratuib Web site. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm275758.htm. Accessed January 27 2104.

    • Search Google Scholar
    • Export Citation
  • 157.

    GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:18301835.

    • Search Google Scholar
    • Export Citation
  • 158.

    ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:969106.

    • Search Google Scholar
    • Export Citation
  • 159.

    MilesDHarbeckNEscudierB. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol2011;29:8388.

    • Search Google Scholar
    • Export Citation
  • 160.

    MilesDW. Reply to P. Potemski. J Clin Oncol2011;29:e386.

  • 161.

    PotemskiP. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?J Clin Oncol2011;29:e384385.

    • Search Google Scholar
    • Export Citation
  • 162.

    HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672680.

    • Search Google Scholar
    • Export Citation
  • 163.

    TolJKoopmanMCatsA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563572.

  • 164.

    Erbitux [package insert]. Branchburg, NJ: ImClone Systems Incorporated; 2013.

  • 165.

    ValeCLTierneyJFFisherD. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev2012;38:618625.

    • Search Google Scholar
    • Export Citation
  • 166.

    Vectibix [Package insert]. Thousand Oaks, CA: Amgen Inc.; 2013.

  • 167.

    HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963964.

    • Search Google Scholar
    • Export Citation
  • 168.

    HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529531.

    • Search Google Scholar
    • Export Citation
  • 169.

    ReschGSchaberl-MoserRKierP. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol2011;22:486487.

    • Search Google Scholar
    • Export Citation
  • 170.

    BerlinJVan CutsemEPeetersM. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials [abstract]. J Clin Oncol2007;25(Suppl):Abstract 4134.

    • Search Google Scholar
    • Export Citation
  • 171.

    JonkerDJO'CallaghanCJKarapetisCS. Cetuximab for the treatment of colorectal cancer. N Engl J Med2007;357:20402048.

  • 172.

    LievreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 173.

    PetrelliFBorgonovoKBarniS. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol2013;8:173181.

    • Search Google Scholar
    • Export Citation
  • 174.

    StintzingSKapaunCLaubenderRP. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer2013;132:236245.

    • Search Google Scholar
    • Export Citation
  • 175.

    Van CutsemETejparSVanbeckevoortD. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol2012;30:28612868.

    • Search Google Scholar
    • Export Citation
  • 176.

    BurtnessBAnadkatMBastiS. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw2009;7(Suppl 1):S521.

    • Search Google Scholar
    • Export Citation
  • 177.

    PetrelliFCabidduMBorgonovoKBarniS. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol2012;23:16721679.

    • Search Google Scholar
    • Export Citation
  • 178.

    ZhangDYeJXuTXiongB. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother2013;25:170175.

    • Search Google Scholar
    • Export Citation
  • 179.

    GrotheyALenzHJ. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol2012;30:17351737.

  • 180.

    AntonacopoulouAGTsamandasACPetsasT. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology2008;53:698706.

  • 181.

    McKayJAMurrayLJCurranS. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer2002;38:22582264.

    • Search Google Scholar
    • Export Citation
  • 182.

    SpanoJPLagorceCAtlanD. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol2005;16:102108.

  • 183.

    YenLCUenYHWuDC. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg2010;251:254260.

    • Search Google Scholar
    • Export Citation
  • 184.

    HechtJRMitchellENeubauerMA. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res2010;16:22052213.

    • Search Google Scholar
    • Export Citation
  • 185.

    SaltzLBMeropolNJLoehrerPJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:12011208.

    • Search Google Scholar
    • Export Citation
  • 186.

    BaselgaJRosenN. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol2008;26:15821584.

  • 187.

    De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508515.

    • Search Google Scholar
    • Export Citation
  • 188.

    KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:17571765.

    • Search Google Scholar
    • Export Citation
  • 189.

    Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:32303237.

    • Search Google Scholar
    • Export Citation
  • 190.

    TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl):Abstract 4001.

    • Search Google Scholar
    • Export Citation
  • 191.

    DouillardJYOlinerKSSienaS. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med2013;369:10231034.

  • 192.

    ArtaleSSartore-BianchiAVeroneseSM. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:42174219.

    • Search Google Scholar
    • Export Citation
  • 193.

    Etienne-GrimaldiMCFormentoJLFrancoualM. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res2008;14:48304835.

    • Search Google Scholar
    • Export Citation
  • 194.

    KnijnNMekenkampLJKlompM. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer2011;104:10201026.

    • Search Google Scholar
    • Export Citation
  • 195.

    WangHLLopateguiJAminMBPattersonSD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol2010;17:2332.

    • Search Google Scholar
    • Export Citation
  • 196.

    MonzonFAOginoSHammondMEH. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med2009;133:16001606.

    • Search Google Scholar
    • Export Citation
  • 197.

    RothADTejparSDelorenziM. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol2010;28:466474.

    • Search Google Scholar
    • Export Citation
  • 198.

    DahabrehIJTerasawaTCastaldiPJTrikalinosTA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med2011;154:3749.

    • Search Google Scholar
    • Export Citation
  • 199.

    De RoockWJonkerDJDi NicolantonioF. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA2010;304:18121820.

    • Search Google Scholar
    • Export Citation
  • 200.

    TejparSCelikISchlichtingM. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol2012;30:35703577.

    • Search Google Scholar
    • Export Citation
  • 201.

    PeetersMDouillardJYVan CutsemE. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol2013;31:759765.

    • Search Google Scholar
    • Export Citation
  • 202.

    StintzingSJungARossiusL. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients [abstract]. Presented at the European Cancer Congress 2013; September27-October 12013; Amsterdam, The Netherlands. Abstract LBA17.

    • Search Google Scholar
    • Export Citation
  • 203.

    TolJNagtegaalIDPuntCJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med2009;361:9899.

  • 204.

    MaughanTSAdamsRASmithCG. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet2011;377:21032114.

    • Search Google Scholar
    • Export Citation
  • 205.

    DaviesHBignellGRCoxC. Mutations of the BRAF gene in human cancer. Nature2002;417:949954.

  • 206.

    IkenoueTHikibaYKanaiF. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res2003;63:81328137.

    • Search Google Scholar
    • Export Citation
  • 207.

    WanPTGarnettMJRoeSM. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell2004;116:855867.

  • 208.

    BokemeyerCCutsemEVRougierP. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer2012;48:14661475.

    • Search Google Scholar
    • Export Citation
  • 209.

    Van CutsemEKohneCHLangI. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol2011;29:20112019.

    • Search Google Scholar
    • Export Citation
  • 210.

    Di NicolantonioFMartiniMMolinariF. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008;26:57055712.

    • Search Google Scholar
    • Export Citation
  • 211.

    Laurent-PuigPCayreAManceauG. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol2009;27:59245930.

    • Search Google Scholar
    • Export Citation
  • 212.

    LoupakisFRuzzoACremoliniC. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer2009;101:715721.

    • Search Google Scholar
    • Export Citation
  • 213.

    De RoockWClaesBBernasconiD. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol2010;11:753762.

    • Search Google Scholar
    • Export Citation
  • 214.

    SeymourMTBrownSRRichmanS. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC) [abstract]. J Clin Oncol2011;29(Suppl):Abstract 3523.

    • Search Google Scholar
    • Export Citation
  • 215.

    PriceTJHardinghamJELeeCK. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol2011;29:26752682.

    • Search Google Scholar
    • Export Citation
  • 216.

    Safaee ArdekaniGJafarnejadSMTanL. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One2012;7:e47054.

    • Search Google Scholar
    • Export Citation
  • 217.

    SamowitzWSSweeneyCHerrickJ. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res2005;65:60636069.

    • Search Google Scholar
    • Export Citation
  • 218.

    SaridakiZPapadatos-PastosDTzardiM. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer2010;102:17621768.

    • Search Google Scholar
    • Export Citation
  • 219.

    XuQXuATZhuMM. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis2013;14:409416.

    • Search Google Scholar
    • Export Citation
  • 220.

    SantiniDSpotoCLoupakisF. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol2010;21:1565.

    • Search Google Scholar
    • Export Citation
  • 221.

    LangIKohneCHFolprechtG. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer2013;49:439448.

    • Search Google Scholar
    • Export Citation
  • 222.

    MitchellEPPiperdiBLacoutureME. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer2011;10:333339.

    • Search Google Scholar
    • Export Citation
  • 223.

    SobreroAFPeetersMPriceTJ. Final results from study 181: randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol2012;30(Suppl):Abstract 387.

    • Search Google Scholar
    • Export Citation
  • 224.

    BokemeyerCBondarenkoIHartmannJT. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January22-242010; Orlando, Florida. Abstract 428.

    • Search Google Scholar
    • Export Citation
  • 225.

    TaiebJMaughanTBokemeyerC. Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): a pooled analysis of COIN and OPUS study data [abstract]. J Clin Oncol2012;30(Suppl):Abstract 3574.

    • Search Google Scholar
    • Export Citation
  • 226.

    TveitKMGurenTGlimeliusB. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol2012;30:17551762.

    • Search Google Scholar
    • Export Citation
  • 227.

    PrimroseJNFalkSFinch-JonesM. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC study [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3504.

    • Search Google Scholar
    • Export Citation
  • 228.

    DouillardJSienaSCassidyJ. Final results from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first–line metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol2011;29(Suppl):Abstract 3510.

    • Search Google Scholar
    • Export Citation
  • 229.

    HeinemannVFischer von WeikersthalLDeckerT. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [abstract]. J Clin Oncol2013;31:Abstract LBA3506.

    • Search Google Scholar
    • Export Citation
  • 230.

    StintzingSFischer von WeikersthalLDeckerT. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol2012;23:16931699.

    • Search Google Scholar
    • Export Citation
  • 231.

    HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:20782083.

    • Search Google Scholar
    • Export Citation
  • 232.

    GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:12091214.

    • Search Google Scholar
    • Export Citation
  • 233.

    RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:14071412.

    • Search Google Scholar
    • Export Citation
  • 234.

    KimGPSargentDJMahoneyMR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol2009;27:28482854.

    • Search Google Scholar
    • Export Citation
  • 235.

    BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol2013;14:2937.

    • Search Google Scholar
    • Export Citation
  • 236.

    KubickaSGreilRAndreT. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol2013;24:23422349.

    • Search Google Scholar
    • Export Citation
  • 237.

    MasiGLoupakisFSalvatoreL. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO) [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3615.

    • Search Google Scholar
    • Export Citation
  • 238.

    CartwrightTHYimYMYuE. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer2012;11:238246.

    • Search Google Scholar
    • Export Citation
  • 239.

    SeymourMTBrownSRMiddletonG. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol2013;14:749759.

    • Search Google Scholar
    • Export Citation
  • 240.

    SaltzLRubinMHochsterH. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol2001;20:3a. Abstract 7.

    • Search Google Scholar
    • Export Citation
  • 241.

    SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:23112319.

    • Search Google Scholar
    • Export Citation
  • 242.

    ZALTRAP [package insert]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc. /sanofi-aventis U.S. LLC; 2012.

  • 243.

    STIVARGA [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2012.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 567 567 44
PDF Downloads 102 102 19
EPUB Downloads 0 0 0